164 related articles for article (PubMed ID: 37162273)
21. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
22. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.
Haas M; Caron G; Chatonnet F; Manenti S; Alaterre E; Devin J; Delaloy C; Bertolin G; Viel R; Pignarre A; Llamas-Gutierrez F; Marchalot A; Decaux O; Tarte K; Delpy L; Moreaux J; Fest T
Blood; 2022 Apr; 139(15):2316-2337. PubMed ID: 35108359
[TBL] [Abstract][Full Text] [Related]
23. Cdc25C/cdc2/cyclin B, raf/MEK/ERK and PERK/eIF2α/CHOP pathways are involved in forskolin-induced growth inhibition of MM.1S cells by G2/M arrest and mitochondrion-dependent apoptosis.
Yang P; Jiang PW; Li C; Gao MX; Sun YS; Zhang DY; Du WQ; Zhao J; Shi ST; Li Y; Yang T; Cheng L; Li MH
Cell Cycle; 2021 Nov; 20(22):2402-2412. PubMed ID: 34606419
[TBL] [Abstract][Full Text] [Related]
24. PIM Kinases in Multiple Myeloma.
Wu J; Chu E; Kang Y
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
[TBL] [Abstract][Full Text] [Related]
25. Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group.
Bila J; Katodritou E; Guenova M; Basic-Kinda S; Coriu D; Dapcevic M; Ibricevic-Balic L; Ivanaj A; Karanfilski O; Zver S; Beksac M; Terpos E; Dimopoulos MA
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501388
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects.
Rathi A; Kumar D; Hasan GM; Haque MM; Hassan MI
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129995. PubMed ID: 34455019
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma.
Zhao C; Yang D; Ye Y; Chen Z; Sun T; Zhao J; Zhao K; Lu N
Biochem Pharmacol; 2021 Aug; 190():114648. PubMed ID: 34111425
[TBL] [Abstract][Full Text] [Related]
28. Effects of PIM3 in prognosis of colon cancer.
Zhou Y; Zhou YN; Liu SX; Wang J; Ji R; Yan X
Clin Transl Oncol; 2021 Oct; 23(10):2163-2170. PubMed ID: 33928496
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis.
Wu L; Xia L; Chen X; Ruan M; Li L; Xia R
Leuk Res; 2021 Jul; 106():106565. PubMed ID: 33865032
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics.
Wang Y; Xiu J; Ren C; Yu Z
J Cancer; 2021; 12(9):2570-2581. PubMed ID: 33854618
[TBL] [Abstract][Full Text] [Related]
31. Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis.
Maney NJ; Lemos H; Barron-Millar B; Carey C; Herron I; Anderson AE; Mellor AL; Isaacs JD; Pratt AG
Arthritis Rheumatol; 2021 Oct; 73(10):1820-1830. PubMed ID: 33779060
[TBL] [Abstract][Full Text] [Related]
32. A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma.
Iida S; Sunami K; Minami H; Hatake K; Sekiguchi R; Natsume K; Ishikawa N; Rinne M; Taniwaki M
Int J Hematol; 2021 Jun; 113(6):797-806. PubMed ID: 33638035
[TBL] [Abstract][Full Text] [Related]
33. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.
Terpos E; Zamagni E; Lentzsch S; Drake MT; García-Sanz R; Abildgaard N; Ntanasis-Stathopoulos I; Schjesvold F; de la Rubia J; Kyriakou C; Hillengass J; Zweegman S; Cavo M; Moreau P; San-Miguel J; Dimopoulos MA; Munshi N; Durie BGM; Raje N;
Lancet Oncol; 2021 Mar; 22(3):e119-e130. PubMed ID: 33545067
[TBL] [Abstract][Full Text] [Related]
34. The role of Pim kinase in immunomodulation.
Liu Z; Han M; Ding K; Fu R
Am J Cancer Res; 2020; 10(12):4085-4097. PubMed ID: 33414987
[TBL] [Abstract][Full Text] [Related]
35. The Anti-G0 Manifesto: Should a problematic construct (G0) with no biological reality be removed from the cell cycle? Yes!
Cooper S
Bioessays; 2021 Mar; 43(3):e2000270. PubMed ID: 33283297
[TBL] [Abstract][Full Text] [Related]
36. Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma.
Yao R; Xie Y; Sun X; Zhang M; Zhou J; Liu L; Gao J; Xu K
Drug Des Devel Ther; 2020; 14():3983-3993. PubMed ID: 33061303
[TBL] [Abstract][Full Text] [Related]
37. Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma.
Paíno T; González-Méndez L; San-Segundo L; Corchete LA; Hernández-García S; Díaz-Tejedor A; Algarín EM; Mogollón P; Martín-Sánchez M; Gutiérrez NC; Mateos MV; Garayoa M; Ocio EM
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987735
[TBL] [Abstract][Full Text] [Related]
38. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
Panchal NK; Sabina EP
Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
[TBL] [Abstract][Full Text] [Related]
39. TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.
Teramachi J; Tenshin H; Hiasa M; Oda A; Bat-Erdene A; Harada T; Nakamura S; Ashtar M; Shimizu S; Iwasa M; Sogabe K; Oura M; Fujii S; Kagawa K; Miki H; Endo I; Haneji T; Matsumoto T; Abe M
Haematologica; 2021 May; 106(5):1401-1413. PubMed ID: 32273474
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells.
Liu J; Hu Y; Guo Q; Yu X; Shao L; Zhang C
Front Immunol; 2019; 10():2721. PubMed ID: 31849942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
